BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ChamberMaster//Event Calendar 2.0//EN METHOD:PUBLISH X-PUBLISHED-TTL:P1H REFRESH-INTERVAL:P1H CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU DTSTART:20070101T000000 TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:Eastern Daylight Time END:DAYLIGHT BEGIN:STANDARD RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU DTSTART:20070101T000000 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:Eastern Standard Time END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20210309T140000 DTEND;TZID=America/New_York:20210309T153000 X-MICROSOFT-CDO-ALLDAYEVENT:FALSE SUMMARY:Incubating and Launching New Life Science Companies DESCRIPTION:This 90-minute webinar will explore the processes\, considerations\, and other factors behind the incubation and launch of new companies by some of today's leading venture capital firms. We'll address the following key questions and topics: What are common sources of ideas for new companies and how do VC business models facilitate and measure the progress and de-risking of translational science? How do venture firms approach financing a new entity and how do they balance capital at risk and value capture with syndication and/or non-dilutive funding from partnerships? What are venture firms' views on founder equity for inventors\, for initial key team members\, and for their own firms in their capacity as new company founders? What are key steps to creating an ideal initial management team?REGISTER HERESpeakersLewis Geffen \nMember / Co-chair\, Life Sciences and Venture Capital & Emerging Companies Practices\, MintzNessan Bermingham\, PhD \nSerial entrepreneur and investor\; currently \nPresident & CEO\, Triplet Therapeutics\,\nExecutive Chairman\, Korro BioNathaniel Brooks Horwitz \nPrincipal\, Venture Team\, RA Capital Management\; board member of multiple companiesDeborah Palestrant\, PhD \nPartner\, Head of 4:59\, 5AM Ventures X-ALT-DESC;FMTTYPE=text/html:
This 90-minute webinar will explore the processes\, considerations\, and other factors behind the incubation and launch of new companies by some of today&rsquo\;s leading venture capital firms. \;
We&rsquo\;ll address the following key questions and topics: \;
Speakers
Lewis Geffen \;
Member / Co-chair\, \;Life Sciences and Venture Capital &\; Emerging Companies Practices\, Mintz
Nessan Bermingham\, PhD \;
Serial entrepreneur and investor\; currently \;
President &\; CEO\, \;Triplet Therapeutics\,
Executive Chairman\, \;Korro Bio
Nathaniel Brooks Horwitz \;
Principal\, \;Venture Team\, RA Capital Management\; board member of multiple companies
Deborah Palestrant\, PhD \;
Partner\, Head of 4:59\, \;5AM Ventures